

# Capturing Enhanced MTM Services through Development of Encounter Data and Quality Indicator Measures


Christine Gill, Corey Triebwasser, Evan Perlman, Lanlan Xu, Zippora Kiptanui, Karin Johnson, Catherine Cooke, Ilene Harris  
IMPAQ International



## BACKGROUND & OBJECTIVES

The Part D Enhanced Medication Therapy Management (MTM) Model, operated by the Center for Medicare and Medicaid Innovation, tests whether providing Part D sponsors with additional payment incentives and regulatory flexibilities promotes MTM enhancements leading to improved therapeutic outcomes, while reducing Medicare expenditures.

Six Part D sponsors are participating in the Enhanced MTM Model. These sponsors represent approximately 1.7 million of the 43 million Medicare beneficiaries enrolled in Medicare Part D plans.



- Blue Cross and Blue Shield Northern Plains Alliance
- Blue Cross and Blue Shield of Florida
- CVS Health
- Humana
- UnitedHealthcare
- WellCare Prescription Insurance

To accurately monitor Part D plan sponsors' implementation of their approved Enhanced MTM programs and to help evaluate the overall success of the Enhanced MTM Model, the Centers for Medicare & Medicaid Services (CMS) is collecting Enhanced MTM encounter data.

- Enhanced MTM encounters are services delivered to Medicare beneficiaries enrolled in a participating Part D Prescription Drug Plan.

IMPAQ International, LLC is providing technical implementation support services. This includes data collection, analysis, and performance monitoring of participants.

### Enhanced MTM model tests whether:



- No standard measures are in place to measure enhanced MTM services.
- This poster describes the process of developing Enhanced MTM encounter data specifications and monitoring measures.

## ENHANCED MTM ENCOUNTER DATA SPECIFICATIONS

- Interventions and target populations vary between sponsors participating in the Model. Therefore, it was important that the Enhanced MTM encounter data be both comprehensive and flexible.
- Enhanced MTM encounter data elements were designed to:
  - Make use of existing code sets, primarily the Systematized Nomenclature of Medicine—Clinical Terms®, or SNOMED CT®;
  - Align with existing CMS data collection efforts: For example, although pharmacy claim records use National Drug Codes (NDCs), RxNorm Concept Unique Identifiers (RXCUIs) are standardized and used in other CMS reporting contexts such as formulary submissions.



Evaluating & Enhancing Public Programs & Policy  
www.impaqint.com | @impaqint | (443) 259-5500

This material includes SNOMED Clinical Terms® (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO). All rights reserved. SNOMED CT®, was originally created by The College of American Pathologists. "SNOMED" and "SNOMED CT" are registered trademarks of the IHTSDO.

## Example Sequence

Sequence #	Encounter Code & Description	Drug Name & RXCUI
1	448337001: Telemedicine consultation with patient (procedure)	
2	448177004: Adverse drug interaction with drug (disorder)	Aliskiren 150 MG Oral Tablet [RXCUI = 1011738] Lisinopril 10 MG Oral Tablet [RXCUI = 314076]
3	408377007: Compliance issues discussed with patient (finding)	
4	11429006: Consultation (procedure)	
5	447871000124109: Medication therapy management recommendation accepted by prescriber (situation)	
6	395006008: Medication stopped—interaction (situation)	Lisinopril 10 MG Oral Tablet [RXCUI = 314076]

CMS Enhanced MTM encounter data specifications and pilot monitoring measures were published in 2016.

### Data domains:

- Record identifiers
  - Record number
  - Version
  - CMS Contract ID
  - Plan Benefit Package ID
  - Beneficiary ID
  - Beneficiary encounter sequence
- Enhanced MTM service identifiers
  - Date
  - Encounter code with description
    - These can contain the referral source, procedures, medication therapy issues, and outcomes.
- Additional encounter details
  - Provider identifier and type
  - Service location
  - Drug
  - Beneficiary incentive and cost sharing

## QUALITY INDICATOR MEASURES

The selected measures focus on measuring the general delivery of services to various populations of beneficiaries:

- The “at risk” group—the population of beneficiaries targeted for the Enhanced MTM Model.
- The “treated” group—those who actually received enhanced MTM interventions.

Measure	Description
A1. Percentage of hospital-to-home discharges that are followed by an enhanced Medication Therapy Management (MTM) service within 7 days	<p><b>NUMERATOR:</b> Number of hospital discharges in the denominator in which the beneficiary had at least one enhanced MTM service (as defined by having an enhanced MTM encounter record) within seven days (during the hospitalization or within seven days after discharge).</p> <p><b>DENOMINATOR:</b> Number of hospital discharges among beneficiaries who meet targeting criteria of participating Enhanced MTM programs and are discharged alive from an inpatient acute care hospital stay to home (or those who left against medical advice). Discharges within seven or fewer days from the end of the reporting period will be included with the next reporting period to ensure that sponsors are given all seven days to record an enhanced MTM encounter.</p>
A2. Percentage of targeted beneficiaries with at least one medication therapy issue	<p><b>NUMERATOR:</b> Number of beneficiaries in the denominator who either:</p> <ul style="list-style-type: none"> <li>• Have at least one enhanced MTM encounter record with a medication therapy issue code; or</li> <li>• Have at least one enhanced MTM encounter with a procedure or outcome intervention code, suggestive of a medication therapy issue (because it is assumed that these interventions are in response to an identified problem).</li> </ul> <p>A beneficiary who receives an assessment, but does not have any identified problems, is NOT counted in the numerator.</p> <p><b>DENOMINATOR:</b> Number of beneficiaries reported as enrolled in a participating Enhanced MTM Model plan who are targeted within the reporting period</p>
A3. Percentage of MTM recommendations that were implemented within 30 days	<p><b>NUMERATOR:</b> Number of recommendations that had a matching outcome encounter record where the recommendation was implemented within 30 days, where matching is defined as a record with the same RXCUI and an appropriate SNOMED CT code</p> <p><b>DENOMINATOR:</b> Number of unique recommendations when a beneficiary was enrolled in the plan and targeted by a participating Enhanced MTM program for at least 30 days following the encounter date</p>

## CONCLUSIONS

- The new data specifications and pilot monitoring measures create a framework to capture a variety of enhanced MTM services.
- IMPAQ is developing additional Model-wide and plan-specific measures utilizing Enhanced MTM encounter data to more fully capture Model activities.
- Real-world measurement is an inherently iterative process and the new measures will be reviewed and potentially refined to ensure that specifications (e.g., inclusion criteria, required follow-up time) used to construct and calculate the measures align with how data are recorded.

## ACKNOWLEDGEMENTS

We acknowledge the guidance and help of the Model team at the Centers for Medicare & Medicaid Services.